Royalty Pharma plc (RPRX) |
| 63.88 0.77 (1.22%) 09-03 16:00 |
| Open: | 63.565 |
| High: | 63.94 |
| Low: | 62.5 |
| Volume: | 2,761,452 |
| Market Cap: | 28,316(M) |
| PE Ratio: | 12.17 |
| Exchange: | NASDAQ |
| Industry: | Medical - Pharmaceuticals |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 74.68 |
| Resistance 1: | 63.94 |
| Pivot price: | 61.34 |
| Support 1: | 59.12 |
| Support 2: | 56.13 |
| 52w High: | 63.94 |
| 52w Low: | 34.081 |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Financials
| EPS | 1.860 |
| Book Value | 15.330 |
| PEG Ratio | 2.17 |
| Gross Profit | 5.457 |
| Profit Margin (%) | 32.02 |
| Operating Margin (%) | 19.75 |
| Return on Assets (ttm) | 5.1 |
| Return on Equity (ttm) | 14.0 |
Company news
Wed, 02 Sep 2026
Trading the Move, Not the Narrative: (RPRX) Edition - Stock Traders Daily
Tue, 01 Sep 2026
Quarterly Rebalance Ushers High-Quality Names Into GFLW - ETF Database
Tue, 01 Sep 2026
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week High - What's Next? - MarketBeat
Mon, 31 Aug 2026
Royalty Pharma Plc (RPRX) Stock Analysis: Unpacking A 6.41% Potential Upside - DirectorsTalk Interviews
Mon, 31 Aug 2026
Headlands Technologies LLC Invests $5.09 Million in Royalty Pharma PLC $RPRX - MarketBeat
Sun, 23 Aug 2026
RPRX | Royalty Pharma plc Class Financials - Revenue Breakdown - Quiver Quantitative
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
